Brought to you by 
Abgenix, CuraGen in cancer, autoimmune drug deal
30 Nov 2000
Executive Summary
In a five-year deal, Abgenix and CuraGen will co-develop drugs to treat a variety of diseases including autoimmune and cancer. Abgenix buys (uf)$15mm of CuraGen common stock up front, and CuraGen provides research funding of up to $1.5mm each year.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abgenix, CuraGen in cancer, autoimmune drug deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice